AN2 Therapeutics, Inc. SEC filings ANTX

AN2 Therapeutics, Inc. has 384 filings in SEC EDGAR's recent list, going back to Sep 24, 2021. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
S-8 Employee stock plan registration Sep 14, 2026 —
424B3 Prospectus Apr 20, 2026 —
424B5 Prospectus supplement Apr 20, 2026 —
S-3 Shelf registration Apr 9, 2026 —
S-8 Employee stock plan registration Mar 17, 2026 —
S-8 Employee stock plan registration Mar 25, 2025 —
S-8 Employee stock plan registration Mar 29, 2024 —
424B5 Prospectus supplement Aug 16, 2023 —
424B5 Prospectus supplement Apr 14, 2023 —
S-3 Shelf registration Apr 6, 2023 —
S-8 Employee stock plan registration Mar 30, 2023 —
S-8 Employee stock plan registration Mar 29, 2022 —
424B4 Prospectus Mar 28, 2022 —
S-1MEF Filing Mar 24, 2022 —
S-1/A Amended registration statement Mar 21, 2022 —
S-1 Registration statement Mar 4, 2022 —

Showing 16 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ANTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Menlo Park, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1880438

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.